Introduction to NGU Management

The British Association for Sexual Health and HIV (BASHH) recently released the 2026 update for the management of non-gonococcal urethritis (NGU). Urethritis remains a significant clinical concern for men\'s health globally. Therefore, these updated recommendations provide critical insights into the etiology, diagnostic criteria, and therapeutic pathways for both acute and persistent presentations. Specifically, the guideline focuses on identifying the underlying infectious causes to ensure precision in antibiotic therapy.

Core Principles in the Management of Non-gonococcal Urethritis

Diagnosis of NGU relies on a combination of clinical history and objective evidence of inflammation. Clinicians must identify an excess of polymorphonuclear leucocytes in the anterior urethra of symptomatic patients. However, the 2026 guideline stresses that symptoms alone are insufficient for a definitive diagnosis. Consequently, practitioners should utilize Nucleic Acid Amplification Tests (NAATs) to identify specific pathogens. This approach directly improves clinical outcomes and significantly reduces the risk of transmission to sexual partners.

Diagnostic Pathogens and Testing

The primary organisms associated with NGU are Chlamydia trachomatis and Mycoplasma genitalium. Because M. genitalium often exhibits resistance to common antibiotics, determining the specific aetiology is vital. Additionally, non-infectious causes should be considered if pathogens are not detected. NAAT-based screening remains the gold standard for guiding treatment decisions and preventing potential complications like epididymo-orchitis.

Treatment and Partner Notification

Effective management of non-gonococcal urethritis requires both the patient and their sexual partners to complete a full course of treatment. Patients must abstain from all sexual intercourse until they finish their medication and follow-up. Furthermore, clinicians should provide clear health promotion advice to prevent re-infection. Following these behavioral protocols is as important as the pharmacological intervention itself to break the chain of infection.

FAQs: Navigating the 2026 NGU Guidelines

What are the primary causes of NGU in the latest guidelines?

The 2026 BASHH guidelines identify Chlamydia trachomatis and Mycoplasma genitalium as the most common infectious organisms. However, NGU can also stem from non-infectious triggers or other rare pathogens.

When can a patient resume sexual activity after NGU treatment?

Patients should wait until they and their partners have completed the entire treatment course and any necessary follow-up. This ensures that the infection is fully eradicated and prevents immediate re-infection.

Why is testing for Mycoplasma genitalium necessary in NGU cases?

Testing for M. genitalium is crucial because this organism frequently develops resistance to macrolides. Therefore, identifying it through NAAT helps clinicians select the most effective antibiotic regimen from the start.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. While we strive for accuracy, medical knowledge is constantly evolving. Refer to the latest local and national guidelines for clinical practice.

References

1. Crofts M et al. British Association of Sexual Health and HIV National Guideline on the Management of Non-gonococcal Urethritis (NGU), 2026. Int J STD AIDS. 2026 Mar 10. doi: 10.1177/09564624261430584. PMID: 41806362.


2. Centers for Disease Control and Prevention. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4).


3. Soni S et al. British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium, 2025.